Cognition Therapeutics, Inc. (NASDAQ:CGTX) Shares Acquired by Sigma Planning Corp

Sigma Planning Corp increased its holdings in Cognition Therapeutics, Inc. (NASDAQ:CGTX) by 14.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 197,190 shares of the company’s stock after buying an additional 25,050 shares during the quarter. Sigma Planning Corp’s holdings in Cognition Therapeutics were worth $92,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. AWM Investment Company Inc. acquired a new position in shares of Cognition Therapeutics during the first quarter valued at approximately $1,183,000. CM Management LLC lifted its holdings in shares of Cognition Therapeutics by 14.3% in the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after buying an additional 25,000 shares during the period. Mercer Global Advisors Inc. ADV boosted its stake in Cognition Therapeutics by 33.4% during the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after buying an additional 24,050 shares in the last quarter. Bangor Savings Bank grew its holdings in Cognition Therapeutics by 41.6% during the second quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares during the period. Finally, Levin Capital Strategies L.P. bought a new stake in Cognition Therapeutics in the first quarter worth about $55,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Price Performance

Shares of CGTX opened at $0.46 on Monday. Cognition Therapeutics, Inc. has a one year low of $0.34 and a one year high of $2.95. The company has a 50-day moving average of $0.50 and a two-hundred day moving average of $1.20. The stock has a market cap of $19.16 million, a price-to-earnings ratio of -0.48 and a beta of 1.34.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on CGTX shares. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Cognition Therapeutics in a research report on Monday, November 4th. Chardan Capital restated a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a research report on Friday. Cantor Fitzgerald cut Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, B. Riley reissued a “neutral” rating and set a $1.00 price objective (down from $5.00) on shares of Cognition Therapeutics in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.00.

Cognition Therapeutics Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.